Several studies have attempted to risk‐stratify AML patients using gene signatures obtained from GEP, though most of these signatures were correlated with known risk factors and hence of no further clinical benefit, including those associated with mutations in NPM1 (Verhaak et al, 2005), double mutant CEBPA (Wouters et al, 2009) and FLT3‐ITD (Neben et al, 2005). This evidence concerns the gene NPM1 and acute myeloid leukemia.